William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Hershey rejects $23 billion Mondelez takeover offer
-
Ackman's Pershing Square Releases Third Video on Herbalife (HLF); Notes False Claims From President’s Team Member
-
Herbalife (HLF) Litigation May Be Off Table but Damages May Be Greater than Anticipated - Height Securities
-
Ackman releases new Herbalife video; stock climbs
-
Pershing Square Holdings, Ltd. Announces Second Quarter 2016 Investor Call
-
Ackman's Pershing Square Updates on Valeant Pharma (VRX) Options Position
-
WPP AGM Trading Update
-
Leading Investors and Money Managers Exchange Strategies at Sold-Out Midwest Investment Conference
-
Fitch Affirms Pershing Square Holdings, Ltd.'s 'BBB+' Ratings; Outlook Stable
-
Ackman's Pershing Square posts losses again in May
-
Valeant's former CEO to receive $9 million severance payment, other fees
-
Valeant Pharma (VRX) Rejected Joint Takeda, TPG Takeover Approach - WSJ
-
10 Things You Need to Know About the 10-Year Anniversary of A Celebration of Heroes, Heart and Hope Gala
-
Activist investor heavyweights form new lobbying arm
-
Ackman's Pershing Square's 13F Shows Increased Stake in Restaurant Brands (QSR), Valeant (VRX), Lowered Stake in Air Products (APD), Mondelez (MDLZ), More ...
-
Following Perrigo's (PRGO) Q1 Results, Some Question Valeant's (VRX) New CEO Pick
-
Hedge fund managers give stock picks in Vegas at SALT conference
-
Key player in Pershing Square's Valeant bet leaving firm
-
Ackman's Pershing Square cuts stake in Zoetis
-
S&P Affirms Ratings on Mondelez Int'l (MDLZ); Outlook Raised to Stable
-
Best-paid U.S. hedge fund managers take home $13 billion
-
Ackman's Pershing Square seeks to sell Zoetis shares for $800 million: NYT
-
Bill Ackman to Sell $800M in Zoetis (ZTS) Stock - NYT
-
Midas touch gone, hedge fund industry's influence may be waning
-
Midas touch gone, hedge fund industry's influence may be waning
-
Midas touch gone, hedge fund industry's influence may be waning
-
Midas touch gone, hedge fund industry's influence may be waning
-
New Mexico public employees to exit Ackman's Pershing Square
-
Herbalife in advanced talks to settle FTC probe, issues remain
-
The Pershing Square Sohn Cancer Research Alliance Awards Funding to Seven New York City-Based Cancer Research Scientists
-
Activism is 'alive and well' - Bill Ackman
-
Risk of being short Herbalife (HLF) at $59 is 'low' citing historic valuation multiples - Ackman
-
Herbalife (HLF) Short Position Remains the Same - Ackman
-
Valeant Pharma (VRX) may change its name at some point - Bill Ackman
-
Coca Cola (KO) product causes harm - Bill Ackman
-
Ackman defends Valeant, hints at more changes
-
Valeant Pharma (VRX) has no plans to sell 'crown jewel' assets - Bill Ackman
-
Bill Ackman regrets investing in Valeant Pharma (VRX)
-
Valeant Pharma (VRX) is not a 'sewer' - Ackman
-
Ackman compares Valeant Pharma (VRX) investment now to Warren Buffett's investment in Goldman Sachs (GS) in 2009
-
Valeant Pharma (VRX) Sharply Lower, But on Watch Ahead of Ackman CNBC Interview
-
Warren Buffett Comments on Valeant Pharma (VRX)
-
Buffett says Berkshire 'fine' with Trump or Clinton
-
Valeant annual report reveals new issues, company overhauls board
-
WPP Quarterly Trading Update
-
Valeant to name four new directors as soon as Friday: WSJ
-
Bill Ackman says that he expects Valeant Pharma (VRX) to file its 10k by Friday
-
Real estate activist Litt bets against IRET
-
Ackman, Valeant pledge reforms after spiking drug prices
-
House Democrats question if Valeant is withholding records

